<DOC>
	<DOCNO>NCT00679783</DOCNO>
	<brief_summary>This Phase II , open label , non randomize correlative study AZD2281 patient recurrent breast ovarian cancer BRCA inherit mutation carrier non-carriers identify objective response rate ass early marker activity assess correlative marker may provide helpful information subsequent clinical trial . Approximately 110 patient 7 center Canada enrol study .</brief_summary>
	<brief_title>Phase II Study AZD2281 Patients With Known BRCA Mutation Status Recurrent High Grade Ovarian Cancer Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically confirm high grade serous and/or undifferentiated carcinoma ovary , fallopian tube peritoneum Oestrogen , progesterone HER2 negative advance adenocarcinoma breast Known BRCA positive breast cancer ovarian cancer , high grade serous undifferentiated tuboovarian carcinoma . Performance status 2 . Any chemotherapy , radiotherapy ( except palliative ) , endocrine immunotherapy within 4 week prior entry Major surgery 4 week enter study must recover effect major surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>BRCA</keyword>
	<keyword>Triple negative</keyword>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
	<keyword>Known BRCA Recurrent High Grade Serious/ Undifferentiated Tubo- Ovarian Carcinoma</keyword>
	<keyword>Known BRCA Triple Negative Breast Cancer</keyword>
</DOC>